To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
News and Press Releases
Have you missed any of our press releases or news? No problem – all recently released information is still available in our news archive.
+ Read more
In case there are still questions from your side, we are looking forward to your messages sent via the contact form on the bottom of the page.
News Archive
05/10/2018
Eckert & Ziegler Takes Measures to Significantly Increase U.S. Availability of GalliaPharm® Pharmaceutical Grade Germanium-68/Gallium-68 Generators
Berlin, Germany
Eckert & Ziegler Strahlen-und-Medizintechnik AG (EZAG), through its wholly owned subsidiary Eckert & Ziegler Radiopharma GmbH (EZR), recently submitted to the U.S. Food and Drug Administration (U.S. FDA) an amendment of its Drug Master File (DMF) for its pharmaceutical grade … Read more
19/06/2018
Eckert & Ziegler is Manufacturing Partner for Bayer’s Innovative Targeted Thorium Conjugates in Europe
Berlin, Germany
Eckert & Ziegler AG, a specialist for scientific, medical, and industrial applications of radioisotopes, has been selected as manufacturing partner for clinical supply of Bayer’s innovative Targeted Thorium Conjugates (TTCs) in Europe. TTCs are a versatile, next-generation targeted alpha … Read more
25/10/2017
Eckert & Ziegler Awards Grants to Young Scientists in Nuclear Medicine
Berlin, Germany
This year’s Eckert & Ziegler Abstract Award went to five nuclear medicine specialists from Germany, Sweden and The Netherlands at the congress of the European Association of Nuclear Medicine (EANM) in Vienna. The prizes were awarded for research work in the fields of oncological … Read more
02/08/2017
GalliaPharm® Ge-68/Ga-68 generator receives approval for United Kingdom
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH has been granted marketing authorization (PL 46734/0001) for GalliaPharm® from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This important milestone makes GalliaPharm® available as a medicinal … Read more
11/05/2017
Eckert & Ziegler invests in capacity expansion for its GalliaPharm® production line
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), signed a supply contract for components for a manufacturing line today, paving the way for the creation of additional capacities for its approved GalliaPharm® … Read more
05/05/2017
Eckert & Ziegler signs agreement to sell its cyclotron division to Alliance Medical
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler AG (ISIN DE 0005659700), signed an agreement today on the sale of its entire cyclotron division to Alliance Medical Ltd. Eckert & Ziegler will receive a payment in cash in the amount of € 13,0 million in return. The … Read more
24/03/2017
EANM/Eckert & Ziegler Abstract Award Submission Ends April 25, 2017
Vienna, Austria
Eckert & Ziegler is one of Europe’s largest manufacturers of isotope products. Together with the Association of Nuclear Medicine (EANM), the umbrella organization for nuclear medicine in Europe, it supports young scientists with travel grants to the annual EANM congress. Five awards of EUR … Read more
02/06/2016
NETSPOT ™ Gallium Ga 68 Dotatate Kit Approved By FDA Using The GalliaPharm® Ge-68/Ga-68 Generator As The Source Of Gallium-68
Advanced Accelerator Applications (AAA – The radiopharmaceutical company headquartered in SAINT-GENIS-POUILLY, France) have obtained approval from the US FDA for their diagnostic imaging NETSPOT ™ Gallium Ga 68 dotatate kit. The kit will be used for the labeling of 68Ga dotatate … Read more
03/02/2016
Eckert & Ziegler expands cooperation program with drug developers in the field of nuclear medicine
Berlin, Germany
Eckert & Ziegler AG, a specialist for isotope-based applications in medicine, science and industry, is expanding its cooperation program with promising drug developers in the field of nuclear medicine and will support Curasight, a spin-off based on research by the group of Professor Andreas … Read more
19/05/2015
IPSEN to acquire all shares in Octreopharm Sciences GmbH
Berlin, Germany
Berlin, 19 May 2015. Eckert & Ziegler Radiopharma GmbH (EZR) and a group of start-up investors have signed a purchase agreement with French pharmaceutical company IPSEN for all shares of Octreopharm Science GmbH (OPS), a drug development company located in Berlin-Buch. The deal, which is subject … Read more
04/12/2014
Eckert & Ziegler receives approval for Gallium-68 generator for cost-effective diagnosis of cancer
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) for its pharmaceutical 68Ge/68Ga generator for the German market. The 68Ge/68Ga generator is the world’s first, approved … Read more
27/06/2014
Eckert & Ziegler: European approval process for Gallium-68 generator successfully completed – world’s first authorization for new, inexpensive method for PET radiolabeling
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical 68Ge/68Ga generators. This achievement marks the conclusion of a comprehensive decentralized evaluation procedure and the first time a … Read more
06/06/2012
Eckert & Ziegler obtains manufacturing authorization for pharmaceutical Gallium-68 generators
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler AG, has been given the manufacturing authorization for its pharmaceutical 68Ge/68Ga generators at the newly-built, GMP-compliant manufacturing facilities in Berlin. The authorization given by the local … Read more
Contact
Eckert & Ziegler
Radiopharma Segment
Robert-Rössle-Straße 10
13125 Berlin
Germany
Robert-Rössle-Straße 10
13125 Berlin
Germany
Get in touch
Do you have questions regarding any of our news? Contact us and we will get back to you as soon as possible.